Clofibrate[2-(4-chlorophenoxy)-2-methylpropionic acid ethyl ester] is a hypo lipidemic drug and is also known as a peroxisome proliferator (1). From the findings that peroxisomal acyl-CoA oxidation is strongly stimulated by added NAD+ and that pyridine nucleotides could not be found in highly purified peroxi somes, it is supposed that NAD+ can cross the peroxisomal membrane and that peroxisomes do not possess their own pyridine nucleotide pool (2).
Peroxisome proliferators are known to raise the CoA concentration in the liver and the CoA increase was proved to be due to an increase in CoA synthesis (3). It is, therefore, interesting to see how clofibrate affects the levels of NAD+, another cofactor necessary for peroxisomal fatty acid oxidation, in the liver of rats. As clofibrate was reported to develop myotonia among the treated patients (4, 5), NAD+ and total nicotinate levels were measured not only in the liver but also in the muscle of the rats administered the clofibrate-containing diets. even in the physiological conditions such as fasting and diabetes (12), which suggests the existence of a mechanism to maintain the NAD+ level within fairly narrow range. It is, therefore, interesting that the three hypolipidemic and peroxisome-proliferating agents tested showed a similar hepatic NAD increasing effect, though CPP and DEHP were somewhat less effective than clofibrate.
In the third experiment, whether an increase in the hepatic NAD+ observed after feeding the clofibrate-diet could be reversed by eliminating clofibrate from the diet was investigated. Clofibrate causes an increase in the liver weight because of hyperplasia and hypertrophy (13). The results of the third experiment were, therefore, expressed per wet weight and per mg DNA. As shown in Table 3 , the hepatic NAD of the rats which were fed the MF diet containing 0.25% clofibrate for 2 weeks and then the MF diet for 1 more week was not significantly different from that of the control rats when expressed either per gram of tissue or per milligram of DNA.
DISCUSSION
In this report, we showed that administration of clofibrate and other peroxi- 
